Data-driven translational prostate cancer research: from biomarker discovery to clinical decision

J Transl Med. 2020 Mar 7;18(1):119. doi: 10.1186/s12967-020-02281-4.

Abstract

Prostate cancer (PCa) is a common malignant tumor with increasing incidence and high heterogeneity among males worldwide. In the era of big data and artificial intelligence, the paradigm of biomarker discovery is shifting from traditional experimental and small data-based identification toward big data-driven and systems-level screening. Complex interactions between genetic factors and environmental effects provide opportunities for systems modeling of PCa genesis and evolution. We hereby review the current research frontiers in informatics for PCa clinical translation. First, the heterogeneity and complexity in PCa development and clinical theranostics are introduced to raise the concern for PCa systems biology studies. Then biomarkers and risk factors ranging from molecular alternations to clinical phenotype and lifestyle changes are explicated for PCa personalized management. Methodologies and applications for multi-dimensional data integration and computational modeling are discussed. The future perspectives and challenges for PCa systems medicine and holistic healthcare are finally provided.

Keywords: Biomarker discovery; Clinical application; Prostate cancer; Systems medicine; Translational informatics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Artificial Intelligence*
  • Biomarkers
  • Humans
  • Male
  • Precision Medicine
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / genetics
  • Prostatic Neoplasms* / therapy
  • Translational Medical Research

Substances

  • Biomarkers